Replies to post #141587 on Value Microcaps Motherboard

[btmfdr]

I guess the cats out of the bag on this one. I was hoping to pick up a bit more around 40c before things started going.

I think the growth story with RX is really really good. I never heard of Max Fletcher before, but am going to listen to what he writes about in the future!

[10 bagger]

RX.V / BIOYF.....
Come on guys.. I don't really care if it is being pumped or being brought to the attention of another board.. I own it and thats what's important but I think I owned it before $0.26 And I first posted it on Hank's trading 11/15/11 and at that time I owned over 50K and have added since .. Zen is where I got the idea and I wish to thank him for it and of course I should thank the Swing Board for bringing it to the attention of the rest of the world.. Spinning this one will be a lot easier.. hank

http://investorshub.advfn.com/boards/read_msg.aspx?message_id=69032765&txt2find=bioyf

RX.V / BIOYF.....

I suggest you throw out your calculator. On 08/29/11 when Zen posted RX.V it closed at $0.27/share. So, it is roughly 2x the price.

[Rawnoc]

BIOYF / RX.V is a potential multi-bagger home run IMO. Here's why:

(1) BIOYF / RX.V is debt-free, cash-rich making money hand over fist compared to its tiny market cap and growing rapidly. Their key product, Feramax, is getting rave reviews by pharmacists, doctors, and users.

http://www.babycenter.ca/thread/26739/low-iron-anyone
http://www.crohnsforum.com/showthread.php?t=27666
http://www.healthboards.com/boards/4698267-post5.html
http://ivf.ca/forums/topic/20978-feramax-iron-supplements
http://forums.weddingbells.ca/ubbthreads.php?ubb=showflat&Number=3630907
http://www.healthboards.com/boards/anemia/858534-how-much-iron-too-much.html

(2) Last quarter they had +.025 EPS (w/o one-timers of .006). Annualized + growth makes them appear very cheap to me especially vs. future increased potential EPS.

(3) Their pharmaceutical sales division has shown on average +40% sequential growth in sales each quarter for many quaters so far. Over +215% year-over-year growth last quarter with massive gross profitability margins (78.6% company-wide last quarter)

(4) BIOYF / RX.V is expecting to launch 2 new products this year, and 4 more next year.

(5) The CFO has bought shares in the open market several times:
http://canadianinsider.com/node/7?menu_tickersearch=rx.v (that's the last 6 months alone)